Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement

Oct

01

Today In Oncology

FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees

Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Incidence

Cleveland Clinic London Appoints Oncology Vice Chief

NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress

Depression Increases Cancer-Specific Mortality Risks in Common Cancers

Advertisement

© 2026 HSP News Service, L.L.C.